NeuroOne Reports Q2 2026 Earnings with Strong Revenue Growth
NeuroOne (NMTC) reported a significant year-over-year increase in product revenue for its OneRF brain ablation system, growing by 72% to $2.4 million in the second quarter of fiscal 2026 compared to $1.4 million in Q2 2025. The company highlighted positive patient outcomes and new corporate developments.
Tickers: $ZBH
Topics: corporate_development epilepsy_treatment medical_devices neurotechnology